The Honest Company: A Real Turnaround, And A Poor Entry Point

The Honest Company: A Real Turnaround, And A Poor Entry Point

The market is no longer afraid of The Honest Company, and for a contrarian that has become the most important fact about the stock. HNST has roughly doubled year to date — a chunk of that in a 41% single-day surge after second-quarter earnings — and it now sits more than double its 52-week low of $2.07. The fear that once priced this baby-care brand for failure is gone, replaced by the kind of enthusiasm that usually marks the end of a clean entry, not the beginning. The question is no longer whether the restructuring is real. It is what a ~38x forward earnings multiple on a company whose reported revenue is still shrinking actually buys at this price.

The Turnaround Passed The Numbers Test

The numbers behind the re-rating are mostly genuine. Organic revenue — sales left after the operations management deliberately exited — grew 6.7% in the second quarter, accelerating from 3.9% in the first, with consumption growth approaching 8%. Net income of $10.7 million arrived against $3.9 million a year earlier, on a reported gross margin of 48.4% that expanded 800 basis points, and free cash flow swung from negative $3.8 million to positive $35.3 million in the first half. The balance sheet holds roughly $106 million in cash with no meaningful borrowings. Management raised full-year guidance to $319-325 million revenue, $23-25 million adjusted EBITDA, and 5-7% organic growth. Structurally, this is a changed business: wipes and personal care — the growth engine, including adult-targeted flushables and licensed lines — now account for more than 70% of revenue, while the fading diaper franchise has become the tail of the mix. That is why reported revenue is down about 11% while the underlying franchise grows.

The 'Record' Quarter Has A One-Time Layer

The prudent part of the story is less flattering. The 48.4% reported gross margin included a $6.6 million tariff refund; strip that out and the underlying adjusted gross margin was 43.8% — still a solid 340-basis-point improvement, but not the record headline number. The full-year guide embeds roughly a $10 million apparel-liquidation benefit, and the cash-flow swing was juiced by a nearly $23 million inventory drawdown, a working-capital release that will not repeat at that pace. None of this breaks the story. It does cap how fast earnings can compound from here, which is exactly what a buyer should ask when the shares have already doubled.

The Valuation Now Prices Success, Not Failure

That ceiling matters because the market has quoted the company like a compounding winner. The ~$542 million market capitalization, or the ~$436 million enterprise value (market value less net cash), works out to roughly 18x the adjusted EBITDA guidance midpoint — closer to 30x once the non-recurring apparel benefit is stripped out. The ~38x forward earnings multiple sits above consistently profitable staples names like Clorox and Procter & Gamble at about 22x and 21x trailing earnings. A ~1.6x price-to-sales ratio looks cheap next to Procter & Gamble's 3.9x, but those peers grow revenue every year; Honest is guiding full-year revenue down roughly 13%. The market has paid up for a successful restructuring; this is not a GARP bargain.

Patience, Not FOMO, Is The Edge

Sentiment says the trade is crowded. AInvest's aggregate signal already labels the stock a Buy, and the composite and fundamental scores underneath that label remain subdued — the fingerprint of a story the market has already hugged tight. Price action is extended rather than exhausted: the stock trades about 24% above its 50-day moving average near $4.08, more than 60% above its 200-day, with a 14-day RSI in the mid-60s after a 33% run over the past 20 sessions and a 92% advance over 120. The contrarian move here is neither to short a legitimate turnaround nor to pay the top of a momentum pause. It is a patient Hold: the fundamental checkpoints have been met, and the next two quarters will test whether the margin structure holds once the one-offs roll off and management steps up marketing spend. The better risk/reward sits on a deeper pullback toward the low-$4 area or in a base-building phase that lets the market digest a near-doubling.

Investor Takeaway: Honest Company has earned the re-rating, and that is precisely why the entry has gotten worse. I'd rather own a genuinely improved business after it has given some of the froth back than chase it at a forward multiple that assumes every one-time tailwind repeats. I would reassess the thesis if organic growth slips below the 5-7% guided range or if the underlying gross margin can't hold the mid-40s. The turnaround is real; the easy money on it was spent somewhere around the 41% pop.